Home Health Services

Expand your reach, expand your innovation

PanAmerican’s home health services enable more patients to participate in clinical research and enable trials in areas and populations undeserved by traditional clinical research sites. Whether increasing enrollment and retention in traditional trials or making virtual trials possible, PanAmerican has the home health providers to realize any clinical trial.

Home Health Services

  • Informed consent discussions & documentation  
  • Study drug delivery & administration
  • IV infusions
  • Biological sample collection, processing, & packaging
  • Health screenings & vital sign assessments
  • Patient & caregiver training 
  • Monitoring
  • Translations 

Case Study

Client: Small Biopharma Company

Ask: Support the in-home portion of an otherwise virtual trial in Mexico.

Situation: The rare disease trial was not suited to a traditional model and required community outreach and recruitment and various in-home visits.  

PanAmerican Solution: PanAmerican leveraged its staff epidemiologists and local knowledge to identify three communities with disease prevalence and built rapport within these communities and health clinics serving these areas in order to identify participants. PanAmerican home health providers trained each participant and family members on study procedures, attended those visits requiring blood draws and IV infusion, and supported the use of the virtual trial platform. 

PanAmerican Result: A successfully completed trial that hit enrollment targets and produced quality data. What was a trial once thought not feasible, was made a reality by the virtual clinical trial model, technology, and PanAmerican’s ability to recruit outside of traditional research sites.  

“For our virtual trial, PanAmerican assessed the appropriate regions to perform the trial, recruited the participants, and performed the in-home visits. The level of recruitment, retention, and quality data collection were impressive. By eliminating the majority of sites and moving to a virtual model, we were able to execute what we thought was an implausible trial.”